280 related articles for article (PubMed ID: 29648914)
1. TX99 Is a Neutralizing Monoclonal Antibody Against Mouse TIGIT.
Nakamura Y; Naito K; Yamashita-Kanemaru Y; Komori D; Hirochika R; Shibuya A; Shibuya K
Monoclon Antib Immunodiagn Immunother; 2018 Apr; 37(2):105-109. PubMed ID: 29648914
[TBL] [Abstract][Full Text] [Related]
2. Development and Characterization of Novel Monoclonal Antibodies Against Human DNAM-1.
Okumura G; Abe F; Hirochika R; Shibuya A; Shibuya K
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):135-139. PubMed ID: 28498033
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112).
Tahara-Hanaoka S; Shibuya K; Onoda Y; Zhang H; Yamazaki S; Miyamoto A; Honda S; Lanier LL; Shibuya A
Int Immunol; 2004 Apr; 16(4):533-8. PubMed ID: 15039383
[TBL] [Abstract][Full Text] [Related]
4. Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR.
Stanietsky N; Rovis TL; Glasner A; Seidel E; Tsukerman P; Yamin R; Enk J; Jonjic S; Mandelboim O
Eur J Immunol; 2013 Aug; 43(8):2138-50. PubMed ID: 23677581
[TBL] [Abstract][Full Text] [Related]
5. TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells.
Zhang D; Hu W; Xie J; Zhang Y; Zhou B; Liu X; Zhang Y; Su Y; Jin B; Guo S; Zhuang R
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3085-3098. PubMed ID: 29960041
[TBL] [Abstract][Full Text] [Related]
6. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
[TBL] [Abstract][Full Text] [Related]
7. DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses.
Shibuya A; Shibuya K
Int Immunol; 2021 Nov; 33(12):687-692. PubMed ID: 34694361
[TBL] [Abstract][Full Text] [Related]
8. CD155T/TIGIT Signaling Regulates CD8
He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z
Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004
[TBL] [Abstract][Full Text] [Related]
9. Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies.
Preillon J; Cuende J; Rabolli V; Garnero L; Mercier M; Wald N; Pappalardo A; Denies S; Jamart D; Michaux AC; Pirson R; Pitard V; Bagot M; Prasad S; Houthuys E; Brouwer M; Marillier R; Lambolez F; Marchante JR; Nyawouame F; Carter MJ; Baron-Bodo V; Marie-Cardine A; Cragg M; Déchanet-Merville J; Driessens G; Hoofd C
Mol Cancer Ther; 2021 Jan; 20(1):121-131. PubMed ID: 33277440
[TBL] [Abstract][Full Text] [Related]
10. Contribution of inhibitory receptor TIGIT to NK cell education.
He Y; Peng H; Sun R; Wei H; Ljunggren HG; Yokoyama WM; Tian Z
J Autoimmun; 2017 Jul; 81():1-12. PubMed ID: 28438433
[TBL] [Abstract][Full Text] [Related]
11. Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155.
Zhang B; Zhao W; Li H; Chen Y; Tian H; Li L; Zhang L; Gao C; Zheng J
Cancer Immunol Immunother; 2016 Mar; 65(3):305-14. PubMed ID: 26842126
[TBL] [Abstract][Full Text] [Related]
12. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling.
Li M; Xia P; Du Y; Liu S; Huang G; Chen J; Zhang H; Hou N; Cheng X; Zhou L; Li P; Yang X; Fan Z
J Biol Chem; 2014 Jun; 289(25):17647-57. PubMed ID: 24817116
[TBL] [Abstract][Full Text] [Related]
13. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry.
Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817
[TBL] [Abstract][Full Text] [Related]
14. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity.
Stanietsky N; Simic H; Arapovic J; Toporik A; Levy O; Novik A; Levine Z; Beiman M; Dassa L; Achdout H; Stern-Ginossar N; Tsukerman P; Jonjic S; Mandelboim O
Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17858-63. PubMed ID: 19815499
[TBL] [Abstract][Full Text] [Related]
15. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
Inozume T; Yaguchi T; Furuta J; Harada K; Kawakami Y; Shimada S
J Invest Dermatol; 2016 Jan; 136(1):255-63. PubMed ID: 26763445
[TBL] [Abstract][Full Text] [Related]
16. T-cell Ig and ITIM domain regulates natural killer cell activation in murine acute viral hepatitis.
Bi J; Zhang Q; Liang D; Xiong L; Wei H; Sun R; Tian Z
Hepatology; 2014 May; 59(5):1715-25. PubMed ID: 24319005
[TBL] [Abstract][Full Text] [Related]
17. TIGIT as an emerging immune checkpoint.
Harjunpää H; Guillerey C
Clin Exp Immunol; 2020 May; 200(2):108-119. PubMed ID: 31828774
[TBL] [Abstract][Full Text] [Related]
18. Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226.
Fuhrman CA; Yeh WI; Seay HR; Saikumar Lakshmi P; Chopra G; Zhang L; Perry DJ; McClymont SA; Yadav M; Lopez MC; Baker HV; Zhang Y; Li Y; Whitley M; von Schack D; Atkinson MA; Bluestone JA; Brusko TM
J Immunol; 2015 Jul; 195(1):145-55. PubMed ID: 25994968
[TBL] [Abstract][Full Text] [Related]
19. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
[TBL] [Abstract][Full Text] [Related]
20. TIGIT predominantly regulates the immune response via regulatory T cells.
Kurtulus S; Sakuishi K; Ngiow SF; Joller N; Tan DJ; Teng MW; Smyth MJ; Kuchroo VK; Anderson AC
J Clin Invest; 2015 Nov; 125(11):4053-62. PubMed ID: 26413872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
